Suppr超能文献

代谢组学和炎症小体在炎症性肠病中的作用。

Metabolome and inflammasome in inflammatory bowel disease.

机构信息

In Vitro Drug Safety and Biotechnology, University of Toronto, Toronto, Canada.

出版信息

Transl Res. 2012 Jul;160(1):1-28. doi: 10.1016/j.trsl.2011.08.006. Epub 2011 Sep 14.

Abstract

Inflammatory bowel disease (IBD) encompasses several chronic inflammatory disorders leading to the damage of the gastrointestinal tract. The 2 principal forms of these disorders are ulcerative colitis (UC) and Crohn's disease (CD). Bacteria are involved in the etiology of IBD. Many microorganisms have been put forward as causative factors in IBD, but the primary etiologic agents are still not known. The underlying genetic, environmental, and lifestyle issues can affect the individual's predisposition to these diseases. Immune factors identified in IBD are: dysregulation of the innate and adaptive immune system directed against luminal bacteria or their products found in the intestinal lumen and inappropriate immune responses to organisms in the intestine that normally do not elicit a response, possibly because of intrinsic alterations in mucosal barrier function. However, recent advances in basic science research revealed new insights into the role of specific immune cells and their mediators in intestinal inflammation. The inflammatory mediators known as "inflammasome" are a consequence of the metabolic products (metabolom) of cells and commensal or pathogenic bacteria. Elucidation of inflammasome and metabolom has led to the development of biomarkers specific for each disease that are involved into management strategies targeted at altering specific pathogenic mechanisms that have the potential to modify or change the natural course of these disease entities. The review discusses the potential role of biomarkers in monitoring the inflammasome and therefore the severity of intestinal damage. The microbial ecosystem in the human gut in different microhabitats and metabolic niches contribute to the bowel metabolome.In addition, this review will focus on our expanding understanding of microbial factors associated with both the initiation and maintenance of IBD. New insights acquired from murine genetic models of inflammatory bowel disease will also be discussed.

摘要

炎症性肠病(IBD)包括几种导致胃肠道损伤的慢性炎症性疾病。这些疾病的两种主要形式是溃疡性结肠炎(UC)和克罗恩病(CD)。细菌参与了 IBD 的发病机制。许多微生物被提出是 IBD 的致病因素,但主要的病因仍不清楚。潜在的遗传、环境和生活方式问题会影响个体对这些疾病的易感性。在 IBD 中确定的免疫因素有:针对肠道腔中发现的腔细菌或其产物的先天和适应性免疫系统的失调,以及对肠道中通常不会引起反应的生物体的不适当免疫反应,可能是因为粘膜屏障功能的内在改变。然而,基础科学研究的最新进展揭示了特定免疫细胞及其介质在肠道炎症中的作用的新见解。被称为“炎性小体”的炎症介质是细胞和共生或致病菌的代谢产物(代谢组)的结果。炎性小体和代谢组的阐明导致了针对每种疾病的特定生物标志物的发展,这些生物标志物被纳入针对改变特定致病机制的管理策略中,这些机制有可能改变或改变这些疾病实体的自然病程。本文综述讨论了生物标志物在监测炎性小体从而监测肠道损伤严重程度方面的潜在作用。人类肠道中不同微生境和代谢龛位的微生物生态系统有助于肠道代谢组。此外,本文综述还将重点介绍我们对与 IBD 的启动和维持相关的微生物因素的不断增加的理解。还将讨论从炎症性肠病的鼠基因模型中获得的新见解。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验